Kiadis Pharma to list at 12.50 euros per share

Quest for Growth NV

01/07/2015 16:31

BRUSSELS, July 1 (Reuters) - Dutch biotech group Kiadis 
Pharma, which specialises in treatments for blood cancers and 
inherited blood disorders, said it would float on the Amsterdam 
and Brussels stock markets at 12.50 euros a share. 
    The group, which is currently in Phase II trials for its 
main product, leukaemia treatment ATIR 101, had previously set a 
range of 11.00 to 13.75 euros for its initial public offering. 
    At 12.50 euros, Kiadis Pharma will raise 37.6 million euros 
($41.65 million) from its stock market debut if an overallotment 
option is exercised. 
    Kiadis Pharma, which will have a market capitalisation of 
166.4 million euros, will start trading on Thursday. 
    Belgian holding company Quest for Growth  QUFG.BR , which 
has a minority stake in the group, said in a separate 
announcement that existing shareholders had agreed not to sell 
any shares in Kiadis Pharma within 12 months. 
    Kiadis Pharma appointed Kempen as the sole global 
coordinator, which will also be the transaction's joint 
bookrunner together with KBC Securities. Peel Hunt would act as 
co-manager, the company said. 
($1 = 0.9029 euros) 
 
 (Reporting by Robert-Jan Bartunek) 
 ((robertjan.bartunek@thomsonreuters.com; +32 2 2876850; Reuters 
Messaging: robert-jan.bartunek.thomsonreuters.com@reuters.net)) 
 
Keywords: KIADIS IPO/